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Abstract 
Background In the RE-DUAL PCI trial of patients with atrial fibrillation (AF) who underwent 
percutaneous coronary intervention (PCI), dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel 
or ticagrelor) reduced International Society on Thrombosis and Haemostasis bleeding events compared 
with warfarin triple therapy, with noninferiority in overall thromboembolic events. This analysis 
assessed outcomes in relation to patient bleeding and stroke risk profiles, based on the modified HAS-
BLED and CHA2DS2-VASc scores. 
Methods The primary endpoint, major bleeding event (MBE) or clinically relevant nonmajor 
bleeding event (CRNMBE), was compared across study arms in patients categorized by modified HAS-
BLED score 0-2 or ≥3. The composite endpoint of death, thromboembolic event, and unplanned 
revascularization rates was compared in patients categorized by CHA2DS2-VASc score 0-1, 2, or ≥3.  
Results  Risk of MBE or CRNMBE was lower with dabigatran dual therapy (both doses) versus 
warfarin triple therapy, irrespective of modified HAS-BLED category (treatment-by-subgroup interaction 
P-value 0.584 and 0.273 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin). Risk of 
the composite thromboembolic endpoint was similar across CHA2DS2-VASc categories and consistent 
with overall study results (interaction P-value 0.748 and 0.075 for dabigatran 110 and 150 mg dual 
therapy, respectively, vs warfarin). Higher HAS-BLED scores were associated with higher risks of bleeding 
in AF patients after PCI in a treatment-independent analysis.  
Conclusion Dabigatran dual therapy reduced bleeding events irrespective of bleeding risk category 
and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple 
therapy.  
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Highlights 
 RE-DUAL PCI compared dabigatran dual therapy vs warfarin in AF post-PCI 
 This analysis assessed RE-DUAL outcomes relative to bleeding and stroke risk score 
 Dabigatran dual therapy reduced bleeding vs warfarin irrespective of HAS-BLED score 
 Dabigatran dual therapy had similar efficacy to warfarin across CHA2DS2-VASc scores 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
Introduction 
Stroke prevention is a cornerstone of management in patients with atrial fibrillation (AF).1 Many 
patients with AF have associated coronary artery disease, which may require percutaneous coronary 
intervention (PCI) with stenting.2,3 In such patients, the need for oral anticoagulation (OAC) for 
prevention of thromboembolism and antiplatelet therapy for prevention of stent thrombosis and 
coronary events has to be balanced against the risk of serious bleeding from combined OAC and 
antiplatelet therapy.2,4,5 Traditionally, these patients have been managed by triple therapy, consisting of 
a vitamin K antagonist (VKA) plus dual antiplatelet therapy with aspirin and clopidogrel.2,5-9 
Observational studies, randomized trials, and meta-analyses have more recently suggested that dual 
antithrombotic treatment, consisting of a VKA combined with 1 antiplatelet agent, reduces bleeding 
events without increased risk of thromboembolic events when compared with triple therapy.10-14 
Consistent with this, a focused update from the European Society of Cardiology on dual antiplatelet 
therapy in coronary artery disease concluded that the risk of bleeding associated with triple therapy 
increases in proportion to its duration, and recommended that the duration of therapy should be 
minimized, dependent on bleeding and ischemic risks.15 A 2018-dated North American Expert Consensus 
recommended a dual-therapy regimen (OAC plus single antiplatelet therapy with 1 P2Y12 inhibitor) as 
the default strategy for most patients with AF who underwent PCI.5 
 
The landscape of OAC use in patients with AF has been altered by the availability of non-VKA OACs 
(NOACs).16,17 NOACs provide superior or equal safety and similar efficacy, and are more convenient to 
use than VKAs.18-22 The North American Expert Consensus, mentioned above,5 provides a 
recommendation to use a NOAC over a VKA in patients with AF who underwent PCI. The NOAC, 
rivaroxaban, in combination with clopidogrel or ticagrelor was compared in a randomized trial against 
VKAs plus dual antiplatelet therapy in PIONEER-AF, an exploratory randomized trial in patients with AF 
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who underwent PCI.23 PIONEER-AF found that reduced-dose (15 mg daily) dual therapy or a very low-
dose rivaroxaban-based triple therapy strategy decreased rates of “clinically significant” bleeding (a 
composite of major bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction 
[TIMI] criteria or bleeding requiring medical attention) compared with VKAs plus dual antiplatelet 
therapy, but the study was underpowered to demonstrate greater stroke prevention in patients with 
AF22 and the rivaroxaban dose strategies used were not those recommended for AF stroke prevention.  
 
The RE-DUAL PCI trial (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus 
Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous 
Coronary Intervention; NCT 02164864) randomized 2725 PCI patients with AF to treatment with the 
direct thrombin inhibitor, dabigatran, dual therapy in combination with clopidogrel or ticagrelor, or to 
triple therapy consisting of warfarin in combination with clopidogrel or ticagrelor and aspirin.24,25 The 
dabigatran doses investigated (110 or 150 mg bid) are those approved worldwide for the prevention of 
stroke in AF.19,26  
 
The primary endpoint of RE-DUAL PCI was International Society on Thrombosis and Haemostasis major 
bleeding events (MBE) or clinically relevant nonmajor bleeding events (CRNMBE) during follow-up 
(mean duration: 14 months). The incidence of the primary endpoint was 15.4% in the dabigatran 110 mg 
dual therapy group versus 26.9% in the warfarin triple therapy group (hazard ratio [HR]: 0.52; 95% 
confidence interval [CI]: 0.42-0.63; P < 0.001 for noninferiority; P < 0.001 for superiority), and 20.2% in 
the dabigatran 150 mg dual therapy group versus 25.7% in the corresponding warfarin triple therapy 
group, which excluded elderly patients outside the United States (HR: 0.72; 95% CI: 0.58-0.88; P < 0.001 
for noninferiority; P = 0.002 for superiority). The RE-DUAL PCI trial also tested for the noninferiority of 
dabigatran dual therapy (both dabigatran doses combined) compared with warfarin triple therapy in the 
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composite endpoint of thromboembolic events (myocardial infarction, stroke, or systemic embolism), 
death, or unplanned revascularization. The incidence of this composite endpoint was 13.7% in the 
combined dabigatran dual therapy groups versus 13.4% in the warfarin triple therapy group (HR: 1.04; 
95% CI: 0.84-1.29; P = 0.005 for noninferiority).  
 
The RE-DUAL PCI trial included patients with a range of bleeding and stroke risks, categorized 
respectively by the modified HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, 
Bleeding tendency/predisposition, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal 
anti-inflammatory drugs, or alcohol excess)27 and the CHA2DS2-VASc (Congestive heart failure, 
Hypertension, Age ≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex 
category)28 scales. This prespecified ancillary analysis of the RE-DUAL trial assessed safety and efficacy 
outcomes in relation to patient baseline bleeding and stroke risk profiles, based on these clinical risk 
scores. 
 
Methods 
The primary endpoint in this analysis (MBE or CRNMBE) was compared in the 3 study arms of the RE-
DUAL PCI trial in relation to modified HAS-BLED score categories 0-2 or ≥3 (low and high risk, 
respectively). The modification to the HAS-BLED score omitted only the stable international normalized 
ratio (INR) component, as multiple INR measurements were not collected at baseline. Thromboembolic 
events were compared in relation to CHA2DS2-VASc score categories 0-1, 2, or ≥3 (low, moderate, and 
high risk, respectively).  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
8 
 
Statistical analyses 
Clinical characteristics are summarized by modified HAS-BLED and CHA2DS2-VASc
 scores categories, 
categoric variables are reported as frequencies and percentages, and continuous variables as means and 
standard deviations. For comparison of treatment groups with regard to the primary and composite 
thromboembolic endpoints within the modified HAS-BLED and CHA2DS2-VASc subgroups, respectively, 
stratified Cox proportional hazard regression models, including age group (nonelderly or elderly [<70 or 
≥70 years old in Japan and <80 or ≥80 years old everywhere else]) as a stratifying factor and treatment 
arm (dabigatran 110 mg dual therapy vs warfarin triple therapy; dabigatran 150 mg dual therapy and 
dabigatran 110 mg dual therapy combined vs warfarin triple therapy), were applied. For the dabigatran 
150 mg dual therapy versus warfarin triple therapy comparison, unstratified models were applied 
(excluding elderly patients outside the United States in the warfarin triple therapy group). 
Corresponding HRs and 2-sided 95% Wald CIs for HRs were calculated for the modified HAS-BLED and 
CHA2DS2-VASc
 subgroups. In addition, exploratory treatment-by-subgroup interaction P-values are 
provided. Furthermore, a treatment-independent stratified Cox proportional hazard regression analysis 
was performed including HAS-BLED and CHA2DS2-VASc subgroup, respectively, as the only factor in the 
model. 
 
Results 
Patients 
The clinical characteristics of patients and their therapies at baseline (including antiplatelet therapy and 
antacid medication) are shown in Table I according to bleeding and stroke risk categories. Over half of 
the patients had a modified HAS-BLED score ≥3 and a CHA2DS2-VASc score ≥3 (Table II). 
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As expected, older patients and those with more prevalent comorbidities had higher modified HAS-BLED 
and CHA2DS2-VASc scores. The most common access site was the radial site (63.5% of patients overall). 
Clopidogrel was the most frequently used P2Y12 inhibitor at baseline (in >80% of patients), and tended to 
be prescribed more frequently in patients with higher HAS-BLED and CHA2DS2-VASc scores. While similar 
proportions of patients were prescribed proton pump inhibitors (PPIs) between HAS-BLED groups, more 
patients appeared to be treated with PPIs in the higher CHA2DS2-VASc score groups. 
 
Mean (SD) modified HAS-BLED scores were 2.7 (0.7) and 2.8 (0.7) in the dabigatran 110 mg dual therapy 
versus warfarin triple therapy groups, and 2.6 (0.7) and 2.7 (0.8) in the dabigatran 150 mg dual therapy 
versus warfarin triple therapy groups. Mean (SD) CHA2DS2-VASc scores were 3.7 (1.6), 3.8 (1.5), 3.3 (1.5), 
and 3.6 (1.5) in the respective groups. Of the 981 patients randomized to warfarin triple therapy, 804 
were treated and had valid INR measurements more than 90 days after randomization. In these 804 
patients, the mean percentage of time in the guideline-defined target INR range was not relevantly 
different across the modified HAS-BLED and CHA2DS2-VASc score subgroups (Table III). 
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 Total Modified HAS-BLED CHA2DS2-VASc score 
 N = 2725 0-2 
(n = 943) 
≥3  
(n = 1782) 
0-1 
(n = 203) 
2 
(n = 467) 
≥3  
(n = 2055) 
Mean age, y (SD) 70.8 (8.7) 64.3 (8.8) 74.2 (6.3) 60.4 (7.3) 65.5 (7.5) 73.0 (7.7) 
Age group, n (%)       
Elderly* 458 (16.8) 64 (6.8) 394 (22.1) 0 (0) 17 (3.6) 441 (21.5) 
Nonelderly 2267 (83.2) 879 (93.2) 1388 (77.9) 203 (100) 450 (96.4) 1614 (78.5) 
Male sex, n (%)  2070 (76.0) 777 (82.4) 1293 (72.6) 198 (97.5) 436 (93.4) 1436 (69.9) 
Diabetes mellitus, n (%)
†
 993 (36.4) 285 (30.2) 708 (39.7) 13 (6.4) 65 (13.9) 915 (44.5) 
Mean baseline creatinine clearance, mL/min (SD) 78.0 (29.8) 92. 7 (33.8) 70.3 (24.1) 103.7 (31.5) 92.3 (31.2) 72.2 (26.6) 
Previous MI, n (%) 699 (25.7) 251 (26.6) 448 (25.1) 12 (5.9) 59 (12.6) 628 (30.6) 
Previous CAD, n (%)
†
 1828 (67.1) 593 (62.9) 1235 (69.3) 105 (51.7) 269 (57.6) 1454 (70.8) 
Previous PCI, n (%)
†
 912 (33.5) 285 (30.2) 627 (35.2) 38 (18.7) 115 (24.6) 759 (36.9) 
Previous CABG, n (%)
†
 287 (10.5) 72 (7.6) 215 (12.1) 9 (4.4) 26 (5.6) 252 (12.3) 
Previous stent thrombosis, n (%)
‡
 68 (2.5) 28 (3.0) 40 (2.2) 2 (1.0) 11 (2.4) 55 (2.7) 
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Previous PE, n (%)
§
 36 (1.3) 8 (0.8) 28 (1.6) 0 (0) 2 (0.4) 34 (1.7) 
Previous stroke, n (%)
†
 226 (8.3) 6 (0.6) 220 (12.3) 0 (0) 2 (0.4) 224 (10.9) 
Previous SE, n (%)
†
 21 (0.8) 3 (0.3) 18 (1.0) 0 (0) 0 (0) 21 (1.0) 
Previous stroke/TIA, n (%)
†
 317 (11.6) 25 (2.7) 292 (16.4) 0 (0) 2 (0.4) 315 (15.3) 
Type of AF, n (%)
†
       
Persistent  484 (17.8) 169 (17.9) 315 (17.7) 37 (18.2) 93 (19.9) 354 (17.2) 
Permanent  888 (32.6) 284 (30.1) 604 (33.9) 45 (22.2) 128 (27.4) 715 (34.8) 
Paroxysmal  1351 (49.6) 488 (51.7) 863 (48.4) 119 (58.6) 246 (52.7) 986 (48.0) 
Indication for PCI, n (%)       
Stable angina or positive stress test  1182 (43.4) 392 (41.6) 790 (44.3) 81 (39.9) 213 (45.6) 888 (43.2) 
ACS 1375 (50.5) 490 (52.0) 885 (49.7) 113 (55.7) 220 (47.1) 1042 (50.7) 
Staged procedure  462 (17.0) 155 (16.4) 307 (17.2) 37 (18.2) 70 (15.0) 355 (17.3) 
Other  170 (6.2) 63 (6.7) 107 (6.0) 12 (5.9) 34 (7.3) 124 (6.0) 
Type of stent, n (%)
||
       
BMS 404 (14.8) 143 (15.2) 261 (14.6) 21 (10.3) 71 (15.2) 312 (15.2) 
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DES 2251 (82.6) 766 (81.2) 1485 (83.3) 176 (86.7) 383 (82.0) 1692 (82.3) 
DES and BMS 41 (1.5) 18 (1.9) 23 (1.3) 4 (2.0) 7 (1.5) 30 (1.5) 
Other 21 (0.8) 13 (1.4) 8 (0.4) 1 (0.5) 6 (1.3) 14 (0.7) 
Access site, n (%)
††
 
Radial 
Femoral 
 
1731 (63.5) 
972 (35.7) 
 
623 (66.1) 
308 (32.7) 
 
1108 (62.2) 
664 (37.3) 
 
133 (65.5) 
65 (32.0) 
 
326 (69.8) 
138 (29.6) 
 
1272 (61.9) 
769 (37.4) 
Antiplatelet medications at baseline, n (%) 
Clopidogrel 
Ticagrelor 
2693 (98.8) 
2363 (86.7) 
327 (12.0) 
915 (97.0) 
787 (83.5) 
131 (13.9) 
1778 (99.8) 
1576 (88.4) 
196 (11.0) 
198 (97.5) 
171 (84.2) 
34 (16.7) 
459 (98.3) 
398 (85.2) 
61 (13.1) 
2036 (99.1) 
1794 (87.3) 
232 (11.3) 
Antacid medications at baseline 
PPI 
H2 blocker 
Other 
1739 (63.8) 
1641 (60.2) 
140 (5.1) 
41 (1.5) 
601 (63.7) 
564 (59.8) 
51 (5.4) 
17 (1.8) 
1138 (63.9) 
1077 (60.4) 
89 (5.0) 
24 (1.3) 
118 (58.1) 
110 (54.2) 
12 (5.9) 
5 (2.5) 
286 (61.2) 
272 (58.2) 
20 (4.3) 
6 (1.3) 
1335 (65.0) 
1259 (61.3) 
108 (5.3) 
30 (1.5) 
ACS, acute coronary syndrome; AF, atrial fibrillation; BMS, bare-metal stent; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHA2DS2-VASc, Congestive heart 
failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65-74 years, Sex category; DES, drug-eluting stent; HAS-BLED, 
Hypertension, Abnormal renal and liver function, Stroke, Bleeding tendency/predisposition, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-
inflammatory drugs, or alcohol excess; MI, myocardial infarction; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PPI, proton pump inhibitors; SD, standard 
deviation; SE, systemic embolism; TIA, transient ischemic attack.  
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* Elderly: patients aged ≥80 years old (≥70 years old in Japan). 
† 
Data missing from 1 patient (1 in the HAS-BLED 0-2, and in the CHA2DS2-VASc 0-1 group). 
‡ 
Data missing from 44 
patients (18 and 26 as well as 4, 12, and 28 patients in the HAS-BLED 0-2, HAS-BLED ≥3, CHA2DS2-VASc 0-1, CHA2DS2-VASc 2, and CHA2DS2-VASc ≥3 groups, respectively). 
§ 
Data 
missing from 8 patients (4 and 4 as well as 1, 1, and 6 patients in the HAS-BLED 0-2, HAS-BLED ≥3, CHA2DS2-VASc 0-1, CHA2DS2-VASc 2, and CHA2DS2-VASc ≥3 groups, 
respectively). 
||
 Data missing from 8 patients (3 and 5, as well as 1 and 7, in the HAS-BLED 0-2, HAS-BLED ≥3, CHA2DS2-VASc 0-1, and CHA2DS2-VASc ≥3 groups, respectively). 
†† 
Data missing from 22 patients (12 and 10 as well as 5, 3, and 14 patients in the HAS-BLED 0-2, HAS-BLED ≥3, CHA2DS2-VASc 0-1, CHA2DS2-VASc 2, and CHA2DS2-VASc ≥3 groups, 
respectively).  
 
Table I 
Clinical characteristics in relation to modified HAS-BLED and CHA2DS2-VASc scores 
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 CHA2DS2-VASc score, n (%) 
Modified HAS-BLED score, n (%) 0-1 2 ≥3 
0-2 196 (7.2) 313 (11.5) 434 (15.9) 
≥3 7 (0.3) 154 (5.7) 1621 (59.5) 
CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65-74 years, Sex category; HAS-BLED, Hypertension, 
Abnormal renal and liver function, Stroke, Bleeding tendency/predisposition, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs, or alcohol excess. 
 
Table II 
Patients categorized by both modified HAS-BLED and CHA2DS2-VASc scores 
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HAS-BLED or CHA2DS2-VASc score N Percentage of time in the guideline-
defined target INR range, mean (SD)
*
 
HAS-BLED score   
0-2 241 62.0 (25.0) 
≥3 563 65.0 (23.5) 
CHA2DS2-VASc score   
0-1 47 62.6 (25.9) 
2 113 62.5 (23.4) 
≥3 644 64.5 (24.0) 
CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65-74 years, Sex category; HAS-BLED, Hypertension, 
Abnormal renal and liver function, Stroke, Bleeding tendency/predisposition, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs, or alcohol excess; 
INR, international normalized ratio. 
* Treated set. Excludes INR data from the first 90 days. Guideline-defined target INR is 2.0-3.0. For Japanese patients ≥70 years old the target range is 2.0-2.6. 
 
Table III 
Percentage of time in the guideline-defined target INR range for the warfarin triple therapy group according to modified HAS-BLED or CHA2DS2-
VASc score category 
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Bleeding events: primary endpoint 
The primary endpoint (MBE or CRNMBE) was more frequent in patients in HAS-BLED category ≥3 versus 0-2 in the treatment-independent Cox regression 
analysis (HR 1.41; 95% CI 1.17-1.71) (Figure 1A).  
 
Risk of bleeding events was lower with dabigatran dual therapy (each dabigatran dose) versus warfarin triple therapy, irrespective of the HAS-BLED category 
(Figure 2). Treatment-by-subgroup interaction P-values were 0.584 and 0.273, respectively, for the dabigatran 110 mg dual therapy versus warfarin triple 
therapy and dabigatran 150 mg dual therapy versus warfarin triple therapy comparisons.  
 
Risks of bleeding events in patients categorized by baseline thromboembolic risk are reported in Supplementary Figure 1A.  
 
Composite thromboembolic endpoint  
HRs for the composite thromboembolic endpoint of death, thromboembolic event, and unplanned revascularization were 0.84 (95% CI 0.52-1.36) and 1.17 
(95% CI 0.78-1.77) for CHA2DS2-VASc categories 2 and ≥3, respectively, versus category 0-1 in the treatment-independent Cox regression analysis (Figure 1B). 
 
There was no consistent trend for the composite thromboembolic endpoint across the dabigatran dose groups: interaction P-values were 0.739 for the 
dabigatran 110 mg dual therapy versus warfarin triple therapy comparison and 0.075 for the dabigatran 150 mg dual therapy versus warfarin triple therapy 
comparison (Figure 3). For the endpoint of definite stent thrombosis by CHA2DS2-VASc score, interaction P-values were 0.990 for the dabigatran 110 mg dual 
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therapy versus warfarin triple therapy comparison and 0.928 for the dabigatran 150 mg dual therapy versus warfarin triple therapy comparison 
(Supplementary Figure 2A). The number of patients with stent thrombosis is generally small, so that interpretation should be done carefully. 
A further analysis was performed to assess thromboembolic events in patients categorized into CHA2DS2-Vasc 0-2, 3-4, and 5+ score groups. No interaction 
was observed for the dabigatran 110 mg dual therapy versus warfarin triple therapy comparison (interaction P-value 0.748). The comparison of the 
dabigatran 150 mg dual therapy versus warfarin triple therapy resulted in an interaction P-value of 0.062 (Supplementary Table I). 
 
Risks of composite thromboembolic events in patients categorized by baseline bleeding risk are reported in Supplementary Figure 1B. For the outcome of 
definite stent thrombosis by HAS-BLED score, results are displayed in Supplementary Figure 2B. Interpretation of the outcome of definite stent thrombosis by 
treatment group is hindered by the limited number of events. 
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CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65-74 years, Sex category; CI, confidence interval; 
CRNMBE, clinically relevant nonmajor bleeding event; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding tendency/predisposition, Elderly age/frailty, Drugs such as 
concomitant aspirin/nonsteroidal anti-inflammatory drugs, or alcohol excess; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MBE, major bleeding event. HRs and 
95% CIs from a treatment-independent Cox-proportional hazard model stratified by age (elderly vs nonelderly). 
 
Figure 1. Treatment-independent Cox regression analysis (A) ISTH MBEs or CRNMBEs by modified HAS-BLED score. (B) Death, thromboembolic events, or 
unplanned revascularization by CHA2DS2-VASc score. 
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CI, confidence interval; CRNMBE, clinically relevant nonmajor bleeding event; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding tendency/predisposition, Elderly 
age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs, or alcohol excess; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MBE, 
major bleeding event. 
* For the comparison with dabigatran 150 mg dual therapy, patients aged ≥80 years (≥70 years in Japan) outside the United States are excluded. 
Interaction P values for treatment and modified HAS-BLED score subgroups. 
HRs and 95% CIs from a Cox-proportional hazard model; stratified by age (elderly vs nonelderly) for dabigatran 110 mg dual therapy versus warfarin triple therapy; unstratified for dabigatran 
150 mg dual therapy versus warfarin triple therapy. 
 
Figure 2. ISTH MBEs or CRNMBEs by modified HAS-BLED score.  
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CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65-74 years, Sex category; CI, confidence interval; HR, 
hazard ratio. 
* For the comparison with dabigatran 150 mg dual therapy, patients aged ≥80 years (≥70 years in Japan) outside the United States are excluded. 
Interaction P values for treatment and CHA2DS2-VASc score subgroups. 
HRs and 95% CIs from a Cox-proportional hazard model; stratified by age (elderly vs nonelderly) for dabigatran 110 mg dual therapy versus warfarin triple therapy; unstratified for dabigatran 
150 mg dual therapy versus warfarin triple therapy. 
 
Figure 3. Death, thromboembolic events, or unplanned revascularization by CHA2DS2-VASc score. 
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Discussion 
In this analysis from the RE-DUAL PCI trial, the principal finding was that the risk of the primary bleeding endpoint (MBE or CRNMBE) was lower for 
dabigatran dual therapy (each dabigatran dose) than warfarin triple therapy, irrespective of the modified HAS-BLED category (0-2 or ≥3). Second, the risk of 
the composite thromboembolic endpoint was similar across CHA2DS2-VASc categories (0-1, 2, and ≥3) and consistent with the overall study results for both 
doses of dabigatran dual therapy versus warfarin triple therapy comparisons. 24 
 
It is reassuring that, irrespective of bleeding risk, dabigatran dual therapy was associated with lower risks of MBEs or CRNMBEs compared with warfarin 
triple therapy in a setting where antiplatelet therapy is needed. Nevertheless, the appropriate use of a bleeding risk score, such as modified HAS-BLED, is to 
draw attention to the modifiable bleeding risk factors and to identify those patients at high risk, to schedule early review and follow-up. Thus, the use of the 
modified HAS-BLED score in patients with AF presenting with an acute coronary syndrome or undergoing PCI may help decision making in this respect. Of 
note, recent analyses have shown that simply focusing on modifiable bleeding risk factors alone is an inferior strategy compared with formal bleeding risk 
assessment using the modified HAS-BLED score in predicting serious bleeding events.29-31 It is noteworthy that, in treatment-independent analysis, the risks 
of MBEs or CRNMBEs were 41% higher in patients who had modified HAS-BLED scores ≥3 (the majority of patients in our study) compared with patients who 
had a lower modified HAS-BLED score (0-2). A high CHA2DS2-VASc score has been reported to be predictive of thromboembolic outcomes in patients with AF 
undergoing PCI.32 No consistent trend in the composite thromboembolic endpoint could be observed for CHA2DS2-VASc scores in our treatment-independent 
analysis. Nevertheless, the CHA2DS2-VASc score was designed for the prediction of stroke in AF, but given that it represents a cluster of common 
cardiovascular risk factors, there is unsurprisingly a relationship to cardiac events. 
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These findings support the view that higher modified HAS-BLED scores do identify higher risk patients—and for these, the absolute treatment benefits 
(regardless of type of OAC treatment) may be greater. The findings also lend support to the new North American expert consensus, which recommends that 
a dual therapy approach should be the “default strategy” for most patients.5 In both the North American and European statements, risk stratification is 
recommended to help choose appropriate therapies, where absolute event rates could play a role.5,15  
 
In relation to the doses of dabigatran dual therapy, rates of MBE/CRNMBE were similar for the 110 mg and 150 mg bid doses (12.2% and 14.6%, respectively) 
in patients with a HAS-BLED score 0-2, and were lower for the 110 mg than 150 mg dose (17.1% and 24.2%, respectively) in patients with a HAS-BLED score 
≥3. This indicates that the choice of dabigatran 110 mg dual therapy is reasonable in patients with AF who are at very high bleeding risk post-PCI, e.g., the 
very elderly, consistent with the European prescribing information for dabigatran.33 
 
A limitation of our study is that, as in any subgroup analysis, it is not powered for formal statistical analyses within each modified HAS-BLED and CHA2DS2-
VASc score category. Therefore, these results should be regarded as exploratory and interpreted with caution. Additionally, a modified HAS-BLED score was 
applied due to the lack of multiple INR measurements at baseline. Because of the limited numbers of events, we have not focused on components of the 
composite thromboembolic endpoint, nor have we subdivided endpoints further by HAS-BLED and CHA2DS2-VASc score categories. Nevertheless, we were 
able to analyze prospectively collected and adjudicated outcomes in the largest published trial of OACs in the setting of patients with AF who underwent 
PCI/stenting. The present ancillary analysis does not address the issue of drug dosing, although no significant interaction was observed for dosing in relation 
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to stroke and bleeding strata. In the main RE-DUAL PCI trial, where dabigatran 110 mg was used as part of dual therapy compared to warfarin, there were 
numerically higher but not significant differences in thromboembolic outcomes, but these comparisons were grossly underpowered. 
 
In conclusion, dabigatran dual therapy (110 or 150 mg) reduced bleeding events compared with warfarin triple therapy, irrespective of bleeding risk, when 
assessed by modified HAS-BLED score. In addition, the risk of thromboembolic events was similar between dabigatran dual therapy and warfarin triple 
therapy, regardless of CHA2DS2-VASc scores.   
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